With 10.83 million shares changed hands, the volume of the stock remained heavier than its average volume of 5.44 million shares. During the session, the Drug Manufacturers – Specialty & Generic company that operates in wider Healthcare sector, reached to the highest price of $3.925 whereas the lowest price it dropped to was $3.48. The 52-week range on AKBA shows that it touched its highest point at $4.08 and its lowest point at $0.80 during that stretch. It currently has a 1-year price target of $7.40. Beta for the stock currently stands at 0.85.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of AKBA was up-trending over the past week, with a rise of 14.62%, but this was up by 53.73% over a month. Three-month performance surged to 103.11% while six-month performance rose 94.06%. The stock gained 266.36% in the past year, while it has gained 106.32% so far this year. A look at the trailing 12-month EPS for AKBA yields -0.22 with Next year EPS estimates of 0.07. For the next quarter, that number is -0.01. This implies an EPS growth rate of 80.61% for this year and 215.62% for next year.
Float and Shares Shorts:
At present, 261.64 million AKBA shares are outstanding with a float of 251.87 million shares on hand for trading. On 2025-05-15, short shares totaled 19.72 million, which was 751.00005 higher than short shares on 1744675200. In addition to Mr. John P. Butler MBA as the firm’s CEO, President & Director, Mr. Erik John Ostrowski M.B.A. serves as its Chief Business Officer, Senior VP, CFO & Treasurer.
Institutional Ownership:
Through their ownership of 0.38880002 of AKBA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, AKBA reported revenue of $57336000.0 and operating income of $13514000.0. The EBITDA in the recently reported quarter was $14041000.0 and diluted EPS was $0.03.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for AKBA since 4 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With AKBA analysts setting a high price target of 10.0 and a low target of 6.0, the average target price over the next 12 months is 7.4. Based on these targets, AKBA could surge 155.1% to reach the target high and rise by 53.06% to reach the target low. Reaching the average price target will result in a growth of 88.78% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.26479 being high and -$0.34627 being low. For AKBA, this leads to a yearly average estimate of -$0.30553.
